Physician profile
Sara K Eckert
NPI 1073759940
$2,589.24
in general payments reported to CMS, 2019-2025
31 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $614 · 2022: $219 · 2023: $238 · 2024: $507 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710 · Education: $45.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.12 |
| Education | $45.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $343.78 | 2021-2024 | Opdualag |
| Amgen INC. | $299.32 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $281.75 | 2021-2024 | |
| Janssen Biotech, INC. | $226.97 | 2025 | Carvykti, Rybrevant, Tecvayli |
| Novartis Pharmaceuticals Corporation | $152.24 | 2021-2025 | |
| Tg Therapeutics, INC. | $120.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $118.35 | 2024-2025 | Tagrisso, Enhertu, Lynparza |
| Pharmaessentia USA Corporation | $113.97 | 2023 | Besremi |
| Abbvie INC. | $91.95 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.02 | 2024-2025 | Libtayo |
| Pfizer INC. | $84.66 | 2024-2025 | |
| Astellas Pharma US INC | $67.03 | 2025 | Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $63.94 | 2023-2025 | Keytruda |
| Alexion Pharmaceuticals, INC. | $58.53 | 2024-2025 | Ultomiris |
| Cumberland Pharmaceuticals, INC. | $54.82 | 2025 | Sancuso |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $51.04 | 2025 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $47.10 | 2025 | Fruzaqla, Ninlaro |
| Glaxosmithkline, LLC. | $42.26 | 2024 | Ojjaara |
| Array Biopharma INC | $32.60 | 2024-2025 | Mektovi, Lorbrena, Xalkori |
| Incyte Corporation | $29.79 | 2025 | Jakafi |
| Puma Biotechnology, INC. | $29.12 | 2025 | |
| Genzyme Corporation | $26.78 | 2025 | |
| Daiichi Sankyo INC. | $26.45 | 2025 | Enhertu |
| Celgene Corporation | $22.69 | 2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $21.29 | 2025 | |
| Taiho Oncology, INC. | $18.82 | 2025 | |
| Eisai INC. | $18.10 | 2025 | |
| Beone Medicines USA, INC. | $18.02 | 2025 | Brukinsa |
| Genentech USA, INC. | $15.52 | 2025 | Tecentriq |
| Agios Pharmaceuticals, INC. | $13.60 | 2024 | Pyrukynd |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Eckert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.